Market prospects build for continuous glucose monitoring after bullish American Diabetes Association results
This article was originally published in Clinica
Excitement is building in the US over the prospects for continuous glucose monitoring (CGM) devices, fuelled by several promising studies released at this year's annual meeting of the American Diabetes Association (ADA), in Washington, DC. "Overall, we were generally surprised by the enthusiasm for CGM," said Morgan Stanley analyst Glenn Reicin, who came away from the meeting concluding that the technology "looks to be a potentially significant market".
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.